• Events
  • Panel discussion: Damiano de Felice to speak at SRI 29
Panel discussion - Event date: 01 Nov 2018

Damiano de Felice to speak at SRI 29

On 1 November, Damiano de Felice, Director of Strategy at the Access to Medicine Foundation, will speak at the SRI 29 Conference in Colorado Springs, USA.

Damiano will join a panel discussion titled ‘Strengthening the ‘’S’’ in ESG’ where he will speak about the framework for analysis and methodology used for the 2018 Access to Medicine Index and the Access to Medicine Foundation’s investor engagement programme. The panel discussion is part of the ‘ESG integration’ workstream of the conference, which brings experts together to share their frameworks for the application of environmental, social, and governance (ESG) metrics in their investment analysis – providing important insights and data for asset managers, advisors, and corporate sustainability professionals.

Seventy-six institutional investors, collectively managing assets in excess of $10 trillion, have already committed to using the Access to Medicine Index in their investment analyses and engagements with companies, by signing the Index investor statement. Damiano will share the importance of coordinating the work of the Access to Medicine Foundation with other standard setting organisations, such as the Sustainability Accounting Standards Board (SASB) – who refer to the indicators and scopes of the Access to Medicine Index in the Exposure Draft of the SASB Standard for the Pharmaceutical Industry.

The SRI Conference is an annual gathering of sustainability professionals, financial advisors, investment managers, members of mission-driven organisations, researchers, and private- and public- sector professionals who share a common goal of deploying capital as a change agent.

Later this month, the Access to Medicine Foundation will be launching the 2018 Access to Medicine Index with a series of events for investors taking place in London (22 November), New York (7 December) and Tokyo (11 December). Keep an eye on our website for more details.

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.